European Urology Open Science最新文献

{"title":"14 PSA based intermediate endpoints to compare cancer specific survival difference between radiotherapy and radical prostatectomy for the treatment of localized prostate cancer","authors":"Wiklund P., Falagario U., Pellegrino F., Lantz A., Akre O.","doi":"10.1016/S2666-1683(25)00017-5","DOIUrl":"10.1016/S2666-1683(25)00017-5","url":null,"abstract":"","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Pages S15-S16"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143097347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"16 Can we \"smell\" something important?","authors":"Cornford P., Dawson J., Yassaie O., Lazarowicz H., Tharmaratnam K., Garyia-Finana M., Probert C.","doi":"10.1016/S2666-1683(25)00019-9","DOIUrl":"10.1016/S2666-1683(25)00019-9","url":null,"abstract":"","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Page S18"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143097387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complex Ureteral Reconstruction via Open or Robotic Ureteroplasty with a Buccal Mucosa Onlay Graft: A Two-center Comparison","authors":"Antonio Andrea Grosso ,&nbsp;Fabrizio Di Maida ,&nbsp;Daniele Paganelli ,&nbsp;Simon Udo Engelmann ,&nbsp;Emily Rinderknecht ,&nbsp;Christoph Eckl ,&nbsp;Sebastian Kälble ,&nbsp;Alexey Barskov ,&nbsp;Rino Oriti ,&nbsp;Sofia Giudici ,&nbsp;Christoph Pickl ,&nbsp;Maximilian Burger ,&nbsp;Andrea Mari ,&nbsp;Andrea Minervini ,&nbsp;Roman Mayr","doi":"10.1016/j.euros.2024.11.002","DOIUrl":"10.1016/j.euros.2024.11.002","url":null,"abstract":"<div><h3>Background and objective</h3><div>Management of a long proximal ureteral stricture is challenging. Buccal mucosal graft (BMG) ureteroplasty is a reliable technique for ureteral reconstruction that avoids the morbidity of bowel interposition or autotransplantation. We compared open and robotic BMG ureteroplasty in a two-center study.</div></div><div><h3>Methods</h3><div>We compared prospectively recorded data for 26 patients who underwent robotic or open BMG ureteroplasty at two academic institutions. Stricture location and length, previous reconstructive interventions, complications, and success rates were assessed and compared. A descriptive statistical analysis was performed.</div></div><div><h3>Key findings and limitations</h3><div>We compared ten patients in the robotic group and 16 in the open group. Stricture location had similar distributions in the open versus robotic group (pelvic junction, 25% vs 20%; proximal ureter, 56.3% vs 60%; middle ureter, 18.7% vs 20%). Median stricture length was significantly longer in the robotic group (26 vs 17 mm; <em>p</em> = 0.01). The rate of previous reconstructive interventions was higher in the robotic group (80% vs 37.5%; <em>p</em> = 0.001). However, previous reconstructive interventions were more complex for the open surgery group. There were no intraoperative complications, and postoperative complication rates were similar in the open and robotic groups (18.7% vs 20%; <em>p</em> = 0.19). Median intraoperative blood loss was significantly lower in the robotic group (300 vs 175 ml; <em>p</em> = 0.03). The success rate was 93.7% in the open group and 90.0% in robotic group.</div></div><div><h3>Conclusions and clinical implications</h3><div>We observed high success rates and low perioperative morbidity for both open and robotic BMG ureteroplasty. The robotic approach was associated with significantly lower intraoperative blood loss.</div></div><div><h3>Patient summary</h3><div>Narrowing of the ureter, which is the tube draining urine from the kidney into the bladder, may need surgical treatment. For reconstruction of long segments, use of a tissue graft from the inside of the mouth is an effective surgical option. Robot-assisted surgery is as safe as open surgery and is associated with lower blood loss.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Pages 125-131"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11722170/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"22 EORTC GUCG 2418 STARBURST: Strategies for treatment adaptation following re-evaluation of the bladder after using primary neoadjuvant systemic therapies: An EORTCplatform trial","authors":"Masson-Lecomte A.","doi":"10.1016/S2666-1683(25)00026-6","DOIUrl":"10.1016/S2666-1683(25)00026-6","url":null,"abstract":"","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Page S25"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143131295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"29 Artificial Intelligence (AI) in the management of prostate cancer - Current state of the art","authors":"Dasgupta P.,&nbsp;Khanna R.,&nbsp;Granados Martinez A.,&nbsp;Raison N.,&nbsp;Ourselin S.,&nbsp;Briganti A.,&nbsp;Montorsi F.","doi":"10.1016/S2666-1683(25)00033-3","DOIUrl":"10.1016/S2666-1683(25)00033-3","url":null,"abstract":"","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Page S33"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143131296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Copyright page","authors":"","doi":"10.1016/S2666-1683(24)01420-4","DOIUrl":"10.1016/S2666-1683(24)01420-4","url":null,"abstract":"","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"70 ","pages":"Page I"},"PeriodicalIF":3.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142747700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Which Measure of Stone Burden is the Best Predictor of Interventional Outcomes in Urolithiasis: A Systematic Review and Meta-analysis by the YAU Urolithiasis Working Group and EAU Urolithiasis Guidelines Panel","authors":"Robert Geraghty ,&nbsp;Amelia Pietropaolo ,&nbsp;Lazaros Tzelves ,&nbsp;Riccardo Lombardo ,&nbsp;Helene Jung ,&nbsp;Andreas Neisius ,&nbsp;Ales Petrik ,&nbsp;Bhaskar K. Somani ,&nbsp;Niall F. Davis ,&nbsp;Giovanni Gambaro ,&nbsp;Romain Boissier ,&nbsp;Andreas Skolarikos ,&nbsp;Thomas Tailly","doi":"10.1016/j.euros.2024.10.024","DOIUrl":"10.1016/j.euros.2024.10.024","url":null,"abstract":"<div><h3>Background and objective</h3><div>Stone size has traditionally been measured in one dimension. This is reflected in most of the literature and in the EAU guidelines. However, recent studies have shown that multidimensional measures provide better prediction of outcomes.</div></div><div><h3>Methods</h3><div>We performed a systematic review and meta-analysis of the prognostic accuracy of measures of stone size (PROSPERO reference CRD42022346967). We considered all studies reporting prognostic accuracy statistics on any intervention for kidney stones (extracorporeal shockwave lithotripsy [ESWL], ureterorenoscopy [URS], or percutaneous nephrolithotomy [PCNL]; Population) using multiplane measurements of stone burden (area in mm² or volume in mm³; Intervention) in comparison to single-plane measurements of stone burden (size in mm; Intervention) for the study-defined stone-free rate (Outcome) in a PICO-framed question. We also assessed complication rates (overall and by Clavien-Dindo grade) and the operative time as secondary outcomes. Searches were made between 1970 and August 2023. We used the DeLong method to compare receiver operating characteristic (ROC) curves.</div></div><div><h3>Key findings and limitations</h3><div>Of 24 studies included in the review, 12 were eligible for comparative analysis with the DeLong test following meta-analysis of prognostic accuracy. For prediction of stone-free status, the area under the ROC curve (AUC) was significantly higher for stone volume than for stone size (0.71 vs 0.67; <em>p</em> &lt; 0.001). Subanalyses confirmed this for ESWL and URS, but not for PCNL. For URS, the AUC was also significantly higher for stone area than for stone size (0.79 vs 0.77; <em>p</em> &lt; 0.001). Throughout all analyses, there was no difference in AUC between stone area and stone volume. There was high risk of bias for all analyses apart from the URS subanalyses.</div></div><div><h3>Conclusions and clinical implications</h3><div>According to the limited data currently available, stone-free rates are predicted with significantly higher accuracy using multidimensional measures of stone burden in comparison to a single linear measurement.</div></div><div><h3>Patient summary</h3><div>We reviewed different ways of measuring the size of stones in the kidney or urinary tract and compared their accuracy in predicting stone-free rates after treatment. We found that measurement of the stone area (2 dimensions) or stone volume (3 dimensions) is better than stone diameter (1 dimension) in predicting stone-free status after treatment.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Pages 22-30"},"PeriodicalIF":3.2,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142698668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment-related Hypertension as a Prognostic Factor for De Novo Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Real-world Evidence Study","authors":"Giuseppe Salfi ,&nbsp;Martino Pedrani ,&nbsp;Selin Candan ,&nbsp;Vasile Urechie ,&nbsp;Sara Merler ,&nbsp;Lorenzo Ruinelli ,&nbsp;Amos Colombo ,&nbsp;Luis Castelo-Branco ,&nbsp;Irene Testi ,&nbsp;Fabio Turco ,&nbsp;Luigi Tortola ,&nbsp;Ursula Vogl ,&nbsp;Luca Gabutti ,&nbsp;Silke Gillessen ,&nbsp;Ricardo Pereira Mestre","doi":"10.1016/j.euros.2024.10.023","DOIUrl":"10.1016/j.euros.2024.10.023","url":null,"abstract":"<div><h3>Background and objective</h3><div>Hypertension (HTN) has been linked to an elevated risk of prostate cancer (PC) development and poorer prognosis in localized cases, and is a common side effect of hormonal PC treatments. However, its relationship with the prognosis of metastatic PC is still unclear. We assessed the prognostic role of treatment-related HTN in patients with de novo metastatic hormone-sensitive PC (mHSPC) undergoing androgen deprivation therapy (ADT) alone or in combination with docetaxel or androgen receptor pathway inhibitors (ARPIs).</div></div><div><h3>Methods</h3><div>Our retrospective analysis included 100 patients with de novo mHSPC treated with ADT, ADT + docetaxel, or ADT + ARPI between 2014 and 2021. Data on clinical variables, antihypertensive drugs, and blood pressure were collected from treatment initiation to 7 mo from ADT start. HTN development within 7 mo from hormonal treatment initiation was graded according to the Common Toxicity Criteria for Adverse Events version 5.0, and Cox analyses were performed for time to castration resistance (TTCR) and overall survival (OS).</div></div><div><h3>Key findings and limitations</h3><div>In the overall population, grade (G) 2–3 HTN development within 7 mo from hormonal treatment initiation was associated with improved TTCR and OS at both univariate (TTCR: 19.8 vs 7.9 mo, hazard ratio [HR]: 0.35, 95% confidence interval [CI]: 0.20–0.63, <em>p</em> &lt; 0.001; OS: 42 vs 18.4 mo, HR: 0.48, 95% CI: 0.26–0.87, <em>p</em> = 0.017) and multivariate (TTCR: HR: 0.41, 95% CI: 0.18–0.91, <em>p</em> = 0.029; OS: HR: 0.42, 95% CI: 0.18–0.97, <em>p</em> = 0.042) analyses. A subgroup analysis of the ADT + ARPI–treated population revealed 7-mo treatment-related G2–3 HTN to be an independent positive prognostic factor in terms of both TTCR and OS multivariate survival analyses (HR: 0.30, 95% CI: 0.09–0.95, <em>p</em> = 0.040, and HR: 0.12, 95% CI: 0.02–0.57, <em>p</em> = 0.008, respectively).</div></div><div><h3>Conclusions and clinical implications</h3><div>The early development or worsening of HTN under hormonal treatment may be associated with longer TTCR and OS in de novo mHSPC patients. Larger studies are needed to validate these findings and explore the potential underlying mechanisms.</div></div><div><h3>Patient summary</h3><div>In this report, we examined the outcomes of patients with metastatic hormone-sensitive prostate cancer and their correlation with hypertension toxicities. We found that patients who developed clinically significant blood pressure toxicity early in oncological treatment experienced longer survival.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Pages 1-10"},"PeriodicalIF":3.2,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142698666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Perioperative Outcomes of Holmium Laser Enucleation of the Prostate for Standard (≤149 ml) Versus Very Large (≥150 ml) Prostate Glands: Retrospective Analysis of a Propensity Score Matched Cohort of 326 Patients","authors":"Jacob Schmidt ,&nbsp;Jorien Krediet ,&nbsp;Holger Beutel ,&nbsp;Ayoub Hidayat Allah ,&nbsp;Nella Gagel ,&nbsp;Isabel Lichy ,&nbsp;Bernhard Ralla ,&nbsp;Maha Ullmann ,&nbsp;Robert Peters ,&nbsp;Frank Friedersdorff ,&nbsp;Martin Kanne","doi":"10.1016/j.euros.2024.10.019","DOIUrl":"10.1016/j.euros.2024.10.019","url":null,"abstract":"<div><h3>Background and objective</h3><div>Our objective was to evaluate whether a very large prostate volume significantly affects the incidence of perioperative complications and compromises outcomes among patients undergoing holmium laser enucleation of the prostate (HoLEP).</div></div><div><h3>Methods</h3><div>We retrospectively analyzed data for 1815 adult patients who underwent HoLEP at Evangelisches Krankenhaus Königin Elisabeth Herzberge, Berlin, between January 2019 and May 2024. Patients were divided into two groups according to their prostate volume: ≤149 ml (group A) and ≥150 ml (group B). Propensity score matching on age, body mass index, American Society of Anesthesiologists physical status, and the presence of an indwelling catheter was used to balance baseline differences. A Mann-Whitney <em>U</em> test was used for comparison of continuous variables between the groups, and a χ² test for comparison of categorical variables, with <em>p</em> &lt; 0.05 considered statistically significant. Postoperative complications were assessed according to the Clavien-Dindo classification.</div></div><div><h3>Key findings and limitations</h3><div>After propensity score matching, 163 matched cases per group were analyzed. Group B had significantly longer median total operative time (76 vs 47 min; <em>p</em> &lt; 0.001), enucleation time (42 vs 26 min; <em>p</em> &lt; 0.001), coagulation time (11 vs 6 min; <em>p</em> &lt; 0.001), and morcellation time (15 vs 7 min; <em>p</em> &lt; 0.001). Clavien-Dindo grade ≥IIIb complications (8.7% vs 1.2%; <em>p</em> = 0.02) and blood transfusion (2.5% vs 0%; <em>p</em> = 0.045) were significantly more frequent in group B. Catheterization time (1.9 vs 2.0 d; <em>p</em> = 0.01) and the proportion of patients with postoperative residual urine volume ≤50 ml (85.2% vs 80.2%; <em>p</em> = 0.18) were comparable between the groups. Limitations include the retrospective and single-center study design.</div></div><div><h3>Conclusions and clinical implications</h3><div>Prostate volume ≥150 ml is associated with a longer operative time, a higher rate of major complications, and a more frequent need for blood transfusion. Therefore, HoLEP for prostate glands ≥150 ml should be performed in experienced high-volume centers.</div></div><div><h3>Patient summary</h3><div>We compared outcomes of laser surgery for enlarged prostate glands of different sizes. We found that while the surgery is generally effective for very large prostates, it takes longer and has a higher risk of complications in comparison to more typical prostate sizes. However, this procedure is still the best treatment available for prostate enlargement and should be carried out in high-volume hospitals specializing in this treatment.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Pages 15-21"},"PeriodicalIF":3.2,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142698667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the Cause of Death for Men with Prostate Cancer Using Official Mortality Statistics or a Dedicated Cause of Death Committee: Results from 30-year ERSPC Rotterdam Data","authors":"Sebastiaan Remmers ,&nbsp;Ivo I. de Vos ,&nbsp;Frederique B. Denijs ,&nbsp;Renée C.A. Leenen ,&nbsp;Tycho M.T.W. Lock ,&nbsp;Arjen Noordzij ,&nbsp;Wim J. Kirkels ,&nbsp;Chris H. Bangma ,&nbsp;Monique J. Roobol ,&nbsp;ERSPC Rotterdam Study Group","doi":"10.1016/j.euros.2024.10.021","DOIUrl":"10.1016/j.euros.2024.10.021","url":null,"abstract":"<div><div>For men with prostate cancer (PCa) within the European Randomized Study of Screening for Prostate Cancer (ERSPC), the cause of death is determined by a Cause of Death Committee (CODC) that evaluates all medical records using a fixed algorithm. The aim of this study was to compare the classification of PCa-specific mortality (PCSM) between the CODC and Statistics Netherlands. We calculated the sensitivity (PCSM agreement divided by total PCSM deaths according to the CODC) and specificity (agreement for other-cause mortality [OCM] divided by total OCM deaths according to the CODC) using the last 21-yr follow-up data from ERSPC Rotterdam. For the core age group (age 55–69 yr at randomization; <em>n</em> = 1732), the sensitivity was 86% (95% CI 83-89) and specificity was 93% (95% CI 91-94), with no statistical difference between the youngest ages and the oldest ages. Extrapolation of our findings to 30 yr of follow-up would result in an expected risk reduction of PCSM of 30% using data from the CODC and 33% using official statistics in favor of screening. In conclusion, our results support the use of official statistics in determining the cause of death, without compromising the main outcome of ERSPC Rotterdam.</div></div><div><h3>Patient summary</h3><div>We compared the classification of prostate cancer death between a dedicated trial committee and official statistics in the Netherlands. We found that official statistics are an accurate representation in determining the cause of death.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Pages 11-14"},"PeriodicalIF":3.2,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142656245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}